Title |
Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling
|
---|---|
Published in |
Blood, November 2006
|
DOI | 10.1182/blood-2006-06-028092 |
Pubmed ID | |
Authors |
Sang-Hoon Sin, Debasmita Roy, Ling Wang, Michelle R. Staudt, Farnaz D. Fakhari, Dhavalkumar D. Patel, David Henry, William J. Harrington, Blossom A. Damania, Dirk P. Dittmer |
Abstract |
The antitumor potency of the mTOR inhibitor rapamycin (sirolimus) is the subject of intense investigations. Primary effusion lymphoma (PEL) appears as an AIDS-defining lymphoma and like Kaposi sarcoma has been linked to Kaposi sarcoma-associated herpesvirus (KSHV). We find that (1) rapamycin is efficacious against PEL in culture and in a murine xenograft model; (2) mTOR, its activator Akt, and its target p70S6 kinase are phosphorylated in PEL; (3) rapamycin inhibits mTOR signaling as determined by S6 phosphorylation; (4) KSHV transcription is unaffected; (5) inhibition of IL-10 signaling correlates with drug sensitivity; and (6) addition of exogenous IL-10 or IL-6 can reverse the rapamycin growth arrest. This validates sirolimus as a new treatment option for PEL. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 2% |
Unknown | 52 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 11 | 21% |
Researcher | 11 | 21% |
Student > Master | 5 | 9% |
Other | 4 | 8% |
Professor > Associate Professor | 4 | 8% |
Other | 10 | 19% |
Unknown | 8 | 15% |
Readers by discipline | Count | As % |
---|---|---|
Agricultural and Biological Sciences | 17 | 32% |
Medicine and Dentistry | 11 | 21% |
Biochemistry, Genetics and Molecular Biology | 6 | 11% |
Immunology and Microbiology | 4 | 8% |
Veterinary Science and Veterinary Medicine | 1 | 2% |
Other | 3 | 6% |
Unknown | 11 | 21% |